Physician profile
Robert Weiss
NPI 1083777403
$3,845.32
in general payments reported to CMS, 2019-2025
27 companies · $53.48 in 2025
The $53.48 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,103 · 2020: $385 · 2021: $671 · 2022: $535 · 2023: $680 · 2024: $418 · 2025: $53.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,152.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $840.29 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Kowa Pharmaceuticals America, INC. | $609.96 | 2019-2025 | Zoryve, Livalo |
| Amgen INC. | $489.75 | 2019-2025 | Repatha, Otezla |
| Idorsia Pharmaceuticals US INC | $484.85 | 2022-2024 | Quviviq |
| Abbvie INC. | $439.17 | 2019-2024 | Vraylar, Ubrelvy, Synthroid |
| Medtronic Vascular, INC. | $106.26 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.88 | 2019-2024 | Trulance, Xifaxan |
| Avanir Pharmaceuticals, INC. | $87.89 | 2019-2022 | |
| Pfizer INC. | $87.81 | 2019-2025 | |
| Astellas Pharma US INC | $84.46 | 2020-2024 | Veozah |
| Lilly USA, LLC | $79.99 | 2022-2024 | Mounjaro |
| Optinose US, INC. | $70.68 | 2022 | |
| Janssen Pharmaceuticals, INC | $66.82 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $62.25 | 2022 | |
| Stryker Corporation | $43.42 | 2024 | Na, Medpor Titan, Smartlock |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.60 | 2019 | |
| Boston Scientific Corporation | $20.59 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.99 | 2019 | |
| Genentech USA, INC. | $18.52 | 2021 | |
| Novo Nordisk INC | $17.27 | 2023 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $16.61 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.54 | 2019 | |
| Eisai INC. | $14.02 | 2024 | |
| Ibsa Pharma INC. | $13.99 | 2019 | |
| Celgene Corporation | $12.73 | 2019 | |
| Allergan, INC. | $12.55 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $12.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.